Phase II trial of amonafide in previously treated patients with advanced ovarian cancer

A Southwest Oncology Group study

Holly H. Gallion, P. Y. Liu, David E. Alberts, Robert V. O'Toole, Janet O'Sullivan, Glenn Mills, Harriet O. Smith, Harry E. Hynes

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Twenty-three patients with metastatic or recurrent Stage III or IV epithelial ovarian cancer who were refractory to or relapsed following previous chemotherapy with cisplatin or a cisplatin analog were entered into a phase II study of amonafide. The starting dose of amonafide was 300 mg/m2 delivered daily over 1 hr by intravenous infusion. In the absence of myelosuppression, the dose of amonafide was escalated by increments of 75 mg/m2 to a maximum of 450 mg/m2. There were 19 eligible and 17 fully evaluable patients. Grade 3 or 4 leukopenia occurred in 14 (74%) patients and grade 3 or 4 thrombocytopenia in 6 (32%) patients. No objective complete or partial responses were observed. Four patients had stable disease for 3, 4, 4.5, and 6 months, respectively. Therefore, amonafide in the doses used in the present trial does not have significant activity in previously treated patients with ovarian cancer.

Original languageEnglish (US)
Pages (from-to)230-232
Number of pages3
JournalGynecologic Oncology
Volume46
Issue number2
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

amonafide
Ovarian Neoplasms
Cisplatin
Leukopenia
Intravenous Infusions
Drug Therapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Gallion, H. H., Liu, P. Y., Alberts, D. E., O'Toole, R. V., O'Sullivan, J., Mills, G., ... Hynes, H. E. (1992). Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: A Southwest Oncology Group study. Gynecologic Oncology, 46(2), 230-232. https://doi.org/10.1016/0090-8258(92)90261-G

Phase II trial of amonafide in previously treated patients with advanced ovarian cancer : A Southwest Oncology Group study. / Gallion, Holly H.; Liu, P. Y.; Alberts, David E.; O'Toole, Robert V.; O'Sullivan, Janet; Mills, Glenn; Smith, Harriet O.; Hynes, Harry E.

In: Gynecologic Oncology, Vol. 46, No. 2, 1992, p. 230-232.

Research output: Contribution to journalArticle

Gallion, Holly H. ; Liu, P. Y. ; Alberts, David E. ; O'Toole, Robert V. ; O'Sullivan, Janet ; Mills, Glenn ; Smith, Harriet O. ; Hynes, Harry E. / Phase II trial of amonafide in previously treated patients with advanced ovarian cancer : A Southwest Oncology Group study. In: Gynecologic Oncology. 1992 ; Vol. 46, No. 2. pp. 230-232.
@article{4ef70be80bb44170ac6ec96934c82c55,
title = "Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: A Southwest Oncology Group study",
abstract = "Twenty-three patients with metastatic or recurrent Stage III or IV epithelial ovarian cancer who were refractory to or relapsed following previous chemotherapy with cisplatin or a cisplatin analog were entered into a phase II study of amonafide. The starting dose of amonafide was 300 mg/m2 delivered daily over 1 hr by intravenous infusion. In the absence of myelosuppression, the dose of amonafide was escalated by increments of 75 mg/m2 to a maximum of 450 mg/m2. There were 19 eligible and 17 fully evaluable patients. Grade 3 or 4 leukopenia occurred in 14 (74{\%}) patients and grade 3 or 4 thrombocytopenia in 6 (32{\%}) patients. No objective complete or partial responses were observed. Four patients had stable disease for 3, 4, 4.5, and 6 months, respectively. Therefore, amonafide in the doses used in the present trial does not have significant activity in previously treated patients with ovarian cancer.",
author = "Gallion, {Holly H.} and Liu, {P. Y.} and Alberts, {David E.} and O'Toole, {Robert V.} and Janet O'Sullivan and Glenn Mills and Smith, {Harriet O.} and Hynes, {Harry E.}",
year = "1992",
doi = "10.1016/0090-8258(92)90261-G",
language = "English (US)",
volume = "46",
pages = "230--232",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Phase II trial of amonafide in previously treated patients with advanced ovarian cancer

T2 - A Southwest Oncology Group study

AU - Gallion, Holly H.

AU - Liu, P. Y.

AU - Alberts, David E.

AU - O'Toole, Robert V.

AU - O'Sullivan, Janet

AU - Mills, Glenn

AU - Smith, Harriet O.

AU - Hynes, Harry E.

PY - 1992

Y1 - 1992

N2 - Twenty-three patients with metastatic or recurrent Stage III or IV epithelial ovarian cancer who were refractory to or relapsed following previous chemotherapy with cisplatin or a cisplatin analog were entered into a phase II study of amonafide. The starting dose of amonafide was 300 mg/m2 delivered daily over 1 hr by intravenous infusion. In the absence of myelosuppression, the dose of amonafide was escalated by increments of 75 mg/m2 to a maximum of 450 mg/m2. There were 19 eligible and 17 fully evaluable patients. Grade 3 or 4 leukopenia occurred in 14 (74%) patients and grade 3 or 4 thrombocytopenia in 6 (32%) patients. No objective complete or partial responses were observed. Four patients had stable disease for 3, 4, 4.5, and 6 months, respectively. Therefore, amonafide in the doses used in the present trial does not have significant activity in previously treated patients with ovarian cancer.

AB - Twenty-three patients with metastatic or recurrent Stage III or IV epithelial ovarian cancer who were refractory to or relapsed following previous chemotherapy with cisplatin or a cisplatin analog were entered into a phase II study of amonafide. The starting dose of amonafide was 300 mg/m2 delivered daily over 1 hr by intravenous infusion. In the absence of myelosuppression, the dose of amonafide was escalated by increments of 75 mg/m2 to a maximum of 450 mg/m2. There were 19 eligible and 17 fully evaluable patients. Grade 3 or 4 leukopenia occurred in 14 (74%) patients and grade 3 or 4 thrombocytopenia in 6 (32%) patients. No objective complete or partial responses were observed. Four patients had stable disease for 3, 4, 4.5, and 6 months, respectively. Therefore, amonafide in the doses used in the present trial does not have significant activity in previously treated patients with ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026786770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026786770&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(92)90261-G

DO - 10.1016/0090-8258(92)90261-G

M3 - Article

VL - 46

SP - 230

EP - 232

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -